Incyte

INCY · NASDAQ

$116.62+$3.37 (+2.97%)TodayMarket closed ·
Prev close $113.25

INCY analyst rating

HoldConsensus of 23 analysts over the last 12 months. 48% rate it a buy.
  • Strong buy0
  • Buy11
  • Hold12
  • Underperform0
  • Sell0

12-month price target · 27 analysts

Average $130.68 (+12.1% upside)

Low
$88.60
Now
$116.62
High
$162.75

Upgrades and downgrades

The latest rating actions, newest first

INCY analyst upgrades, downgrades and rating actions
FirmDateActionRating
Truist SecuritiesOct 14, 2026MaintainsHold
HC Wainwright & Co.Oct 13, 2026MaintainsBuy
RBC CapitalOct 8, 2026MaintainsSector Perform
StifelOct 5, 2026MaintainsBuy
Wells FargoOct 1, 2026MaintainsEqual-Weight
JP MorganSep 28, 2026MaintainsNeutral
HC Wainwright & Co.Sep 28, 2026MaintainsBuy
RBC CapitalSep 22, 2026MaintainsSector Perform
Canaccord GenuityAug 20, 2026InitiatesBuy
HC Wainwright & Co.Aug 20, 2026MaintainsBuy

The case for and against

Updated Oct 14, 2026

Bull case

Incyte is positioned to benefit from a strong mix of durable commercial cash flows and meaningful pipeline optionality, anchored by Jakafi’s growth in myelofibrosis, polycythemia vera, and graft-versus-host disease and supported by pricing power, a constructive partner, and disciplined execution. The dermatology franchise adds a credible long-term offset to future Jakafi pressure, with the topical ruxolitinib program viewed as capable of approaching $0.9B in sales, while Opzelura broadens the company’s reach beyond oncology and reduces concentration risk. Near-term value is also being unlocked by Atebrioz, which brings roughly $205–225M of gross economics, a $25M approval milestone, PRV proceeds that have recently ranged from $195M to $215M, and mid-to-high-single-digit royalties, all against a deep oncology/inflammation pipeline and strong cash generation.

Bear case

Incyte is facing a deteriorating fundamental setup because Jakafi remains heavily exposed to patent expiry in late 2028, with potential generic entry in 2029, and its lifecycle defense still carries a high bar despite multiple combination shots on goal. Its other growth drivers look less dependable: Opzelura faces demand risk after separating CMS benefits, while oncology assets such as Monjuvi, retifanlimab, and the '734 program remain in highly competitive niches with early or unproven readouts. With a DCF implying about $30B of enterprise value and downside modeled at $65, the shares appear vulnerable if upcoming '989 MF data, ESMO oncology updates, or additional dermatology and oncology readouts disappoint.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.